About Cynthia Grosskreutz, MD, PhD

Dr. Grosskreutz is a member of the Glaucoma Service who specializes in the medical management of glaucoma.

After receiving a B.S. in Physics from Washington University and an M.S. in Physics from the University of Iowa, she went on to earn her M.D. and Ph.D. from the University of Iowa College of Medicine. She completed her ophthalmology residency at Harvard Medical School, followed by a glaucoma fellowship at Mass. Eye and Ear.

Departments, Centers, & Programs:

Clinical Interests:




Massachusetts Eye and Ear Infirmary
243 Charles Street
Boston, MA 02114 - 3002
Phone: 617-573-3670
Fax: 671-573-3707

Medical Education

  • PHD, University of Iowa Carver College of Medicine
  • MD, University of Iowa College of Medicine
  • Residency, Massachusetts Eye & Ear
  • Residency, Massachusetts Eye and Ear Infirmary
  • Fellowship, Massachusetts Eye & Ear
  • Fellowship, Massachusetts Eye and Ear Infirmary

American Board Certifications

  • Ophthalmology, American Board of Ophthalmology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Grosskreutz’s research focuses on preclinical drug development for eye disease.


  • View my most recent publications at PubMed

    1. Wang SV, Li N, Rice DS, Grosskreutz CL, Dryja TP, Prasanna G, Lii J, Gagne JJ. Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Open-Angle Glaucoma. Clin Pharmacol Ther. 2019 Oct; 106(4):874-883.

    2. Adams CM, Stacy R, Rangaswamy N, Bigelow C, Grosskreutz CL, Prasanna G. Glaucoma - Next Generation Therapeutics: Impossible to Possible. Pharm Res. 2018 Dec 13; 36(2):25.

    3. Stacy R, Huttner K, Watts J, Peace J, Wirta D, Walters T, Sall K, Seaman J, Ni X, Prasanna G, Mogi M, Adams C, Yan JH, Wald M, He Y, Newton R, Kolega R, Grosskreutz C. A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. Am J Ophthalmol. 2018 08; 192:113-123. 

    4. Grosskreutz CL, Hockey HU, Serra D, Dryja TP. Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1ß by Canakinumab or IL-17A by Secukinumab. Cornea. 2015 Dec; 34(12):1551-6. 

    5. Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015 May; 122(5):939-48.

    View more